KR101600884B1 - Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient - Google Patents
Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient Download PDFInfo
- Publication number
- KR101600884B1 KR101600884B1 KR1020140128784A KR20140128784A KR101600884B1 KR 101600884 B1 KR101600884 B1 KR 101600884B1 KR 1020140128784 A KR1020140128784 A KR 1020140128784A KR 20140128784 A KR20140128784 A KR 20140128784A KR 101600884 B1 KR101600884 B1 KR 101600884B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- acid bacteria
- extract
- lactobacillus
- constipation
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 134
- 239000004310 lactic acid Substances 0.000 title claims abstract description 67
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 67
- 241000894006 Bacteria Species 0.000 title claims abstract description 63
- 206010010774 Constipation Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims description 12
- 239000004480 active ingredient Substances 0.000 title abstract description 11
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title description 3
- 241000522254 Cassia Species 0.000 title 1
- 230000001965 increasing effect Effects 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 241000186660 Lactobacillus Species 0.000 claims description 27
- 229940039696 lactobacillus Drugs 0.000 claims description 25
- 235000013376 functional food Nutrition 0.000 claims description 19
- 230000036541 health Effects 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 210000002784 stomach Anatomy 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 108060001084 Luciferase Proteins 0.000 claims description 5
- 239000005089 Luciferase Substances 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 4
- 241001495410 Enterococcus sp. Species 0.000 claims description 4
- 241000186610 Lactobacillus sp. Species 0.000 claims description 4
- 241001627205 Leuconostoc sp. Species 0.000 claims description 4
- 241000604136 Pediococcus sp. Species 0.000 claims description 4
- 244000184734 Pyrus japonica Species 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 239000008274 jelly Substances 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000192001 Pediococcus Species 0.000 claims description 2
- 241000238371 Sepiidae Species 0.000 claims 2
- 241000192132 Leuconostoc Species 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 27
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 abstract description 9
- 235000014552 Cassia tora Nutrition 0.000 abstract description 9
- 241000411851 herbal medicine Species 0.000 abstract description 8
- 229940124513 senna glycoside Drugs 0.000 abstract description 5
- 229930186851 sennoside Natural products 0.000 abstract description 4
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 abstract description 4
- 229960000503 bisacodyl Drugs 0.000 abstract description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 abstract description 2
- 229960000878 docusate sodium Drugs 0.000 abstract description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 abstract description 2
- 241001426756 Senna tora Species 0.000 abstract 3
- 235000015872 dietary supplement Nutrition 0.000 abstract 3
- 238000000855 fermentation Methods 0.000 description 33
- 230000004151 fermentation Effects 0.000 description 33
- 238000002360 preparation method Methods 0.000 description 32
- 238000004519 manufacturing process Methods 0.000 description 28
- 239000007864 aqueous solution Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 235000013305 food Nutrition 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 10
- 244000201986 Cassia tora Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940099198 dulcolax Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000012730 carminic acid Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 4
- 244000277285 Cassia obtusifolia Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000186605 Lactobacillus paracasei Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000191996 Pediococcus pentosaceus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241001468191 Lactobacillus kefiri Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 210000004513 dentition Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000036346 tooth eruption Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YYAJJKZSQWOLIP-HWKANZROSA-N (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC(\C=C\C(N)=O)=CC=C1O YYAJJKZSQWOLIP-HWKANZROSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000031969 Eye Hemorrhage Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000522641 Senna Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- -1 slices Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 결명자 유산균 발효물을 유효성분으로 하는 변비 개선 또는 예방용 건강기능식품, 변비 치료 또는 예방용 약학 조성물, 및 변의 수분 함량 및 중량을 증가시키는 결명자 유산균 발효물의 제조방법에 관한 것이다.
The present invention relates to a health functional food for improving or preventing constipation, a pharmaceutical composition for treating or preventing constipation, and a method for producing a fermented product of a luciferous lactobacillus which increases the moisture content and weight of the liquor.
변비(Constipation)는 의학적으로 일주일에 3회 이하의 배변이거나, 하루 배변량이 30 g이하일 때 변비라고 정의한다. 정상적인 상태에서는 음식물을 섭취한 후 24시간이면 대변이 되어 배설되나, 변비가 있는 사람은 며칠에 한 번 변을 보거나 매일 보더라도 그 양이 적어 결과적으로 섭취한 음식물의 장내 체류시간이 길어지는 것이다.Constipation is defined as constipation when it is medically less than 3 bowel movements per week or when the bowel movement is 30 g or less per day. Under normal conditions, it is excreted in the stool 24 hours after ingestion of food. However, people with constipation see the stools every few days or even if they see it every day, resulting in a longer stay in the intestinal tract of the resulting food.
변비의 원인으로는 아침식사를 거름으로 인한 대장연동운동의 저하, 식생활의 서구화로 인한 식이섬유의 부족, 운동부족으로 인한 기초체력 및 복근력 저하, 다이어트, 과다한 약물 복용으로 인한 약물 중독 등 여러 가지가 있다.The causes of constipation include a decrease in the intestinal motility caused by eating breakfast, a lack of dietary fiber due to westernization of dietary life, a decrease in basic physical strength and abdominal strength due to lack of exercise, dieting, drug addiction due to excessive use of drugs, have.
예로부터 만병의 근원으로까지 일컬어지고 있는 변비는 식욕이 없고 늘 복부가 팽만한 상태에 있을 뿐 아니라 배설되지 못한 변의 독소가 장을 통하여 혈액에 흡수됨으로써 피부노화를 촉진시키고 두통이나 여드름, 피부 발진 등이 나타나며, 변비가 심하면 배변시 치열의 파손과 치액의 탈출 등 치질의 원인이 되고, 변속에 있는 독소에 의해 대장암까지 발생된다. 또한 변비가 지속되면 체외로 배출되어야 할 콜레스테롤이나 지방이 몸 속에 남아있어서 동맥 경화 또는 담석증을 유발할 수 있으며, 더 나아가서는 고혈압과 심장비대를 일으켜 심장병으로 악화될 수 있다. 이 외에도 뇌졸중, 면역결핍, 시력장애, 정신질환(우울증) 등 다양하고 심각한 2차 질환의 원인이 되므로 변비는 적극적인 예방과 치료가 필요한 중요한 질환이다.Constipation, which is said to be the source of all diseases from ancient times, has no appetite and is not only in a state where the abdomen is always bloated, but also toxins of the unexcited side are absorbed into the blood through the intestines, thereby promoting aging of the skin and causing headache, acne, skin rash And when constipation is severe, it breaks the dentition and escapes the dentition when it is defecated, and it causes the hemorrhoids by the toxin in the shift. If constipation persists, cholesterol or fat that should be excreted outside the body may remain in the body, which may lead to arteriosclerosis or gallstone disease. Furthermore, hypertension and cardiac hypertrophy may be exacerbated by heart disease. In addition, constipation is an important disease that requires active prevention and treatment because it is a cause of diverse and serious secondary diseases such as stroke, immunodeficiency, visual disturbance and mental illness (depression).
이에 현재까지 변비 치료 또는 개선을 위한 다양한 의약품과 건강기능식품이 판매되고 있으나 의약품의 경우 대부분 센나, 대황 등의 안트라퀴논 유도체 성분이 함유된 자극성 약제를 사용함으로써 복통, 설사 등의 부작용과 함께 임신 중 복용이나 지속적인 복용에 문제가 있으며, 건강기능식품의 경우도 과학적으로 그 효과가 충분히 입증되지 못한 것이 대부분이어서 변비 개선의 근본문제를 해결하지 못하고 있어 제품의 신뢰성이 떨어지고 있는 실정이다.To date, various medicines and health functional foods have been sold for the treatment or improvement of constipation. However, most of the medicines use stimulant medicines containing anthraquinone derivatives such as senna and rhubarb, and have side effects such as abdominal pain and diarrhea. And there is a problem in taking or continuously taking the food, and in the case of the functional food, the effect of the scientific function is not sufficiently proved. Therefore, the reliability of the product is deteriorating because the fundamental problem of constipation improvement can not be solved.
결명자는 콩과에 속하는 한해살이 초본으로 초결명자(Cassia obtusifolia L.)와 결명자(Cassia tora L.)의 두 품종이 알려져 있다. 결명자는 초결명, 긴강남차라고도 한다. 초결명자는 중앙아메리카 원산으로 일본 등지에서 결명자는 열대 아시아산으로 중국, 우리나라 등지에서 재배된다. Cassia obtusifolia L. and Cassia ( Cassia obtusifolia L.) Tora L.) are known. The killer is also called the long-lived Kangnam car. Candidates are cultivated in Central Asia, Japan and elsewhere. Tropical Asia is cultivated in China and Korea.
열매의 모양은 불규칙한 육각주상으로 한쪽은 뾰족하다. 외면의 색깔은 황갈 내지 흑갈색이고, 길이 3 내지 6 mm, 지름 2 내지 3.5 mm이다. 종피는 견고하고 윤택하며, 좌우 양측에 광택이 있는 폭이 좁은 한줄의 패어진 무늬가 있고, 약간 특이한 냄새가 난다. C. obtusifolia는 종자가 대립이고, C. tora는 소립이다.The shape of the fruit is irregular hexagonal column, one side is pointed. The color of the outer surface is from yellow to black brown, 3 to 6 mm in length, and 2 to 3.5 mm in diameter. The seed coat is firm and shiny, with a narrow striped pattern with polished sides on both sides and a somewhat unusual smell. C. obtusifolia is seed confrontation, C. tora is small.
결명자는 한방에서 청열명목 작용에 의하여 급성결막염, 안구출혈, 이물질이나 통증을 느끼고, 눈물을 흘리는 경우, 노인의 눈에 발생하는 각막 혼탁현상, 즉 만성진행성질환, 시신경, 망막위축에 기인하는 급속한 시력감퇴, 비만, 혈압이 높고, 정신적 스트레스에 의한 두통, 이명, 눈의 종양을 치료하고, 강압작용으로는 고혈압증 치료, 관상동맥 확장으로 혈유의 저항을 줄여 혈압을 낮추어 주며, 뇌졸중에 의한 반신불수, 경미한 설사작용, 만성질환을 치료하고, 콜레스테롤 저감작용으로는 심혈관질환, 즉 콜레스테롤치가 정상범위를 넘었을 경우나 관상동맥 경화에 의한 협심증을 치료하며, 변비치료는 노인성 변비증, 노인성 고혈압증, 진액부족으로 인한 입이 마르고, 변비 기미에 의한 복부 팽만감, 상습성 변비증 등을 치료하는 것으로 알려져 있다.In case of acute conjunctivitis, ocular hemorrhage, foreign body or pain, and shedding of tears due to the nominal function of cheongryeol in one room, rapid visual acuity due to corneal haze occurring in the eyes of the elderly such as chronic progressive disease, optic nerve, It is the treatment of headache, tinnitus and eye tumor due to decline, obesity, blood pressure, mental stress, treatment of hypertension as coronary artery enlargement, lowering of blood pressure by lowering blood pressure resistance by coronary artery dilation, Mild diarrhea and chronic diseases, cholesterol lowering action is to treat cardiovascular disease, that is, cholesterol level exceeding the normal range or coronary artery stenosis caused by coronary atherosclerosis, and constipation treatment is the treatment of senile constipation, senile hypertension, It is known to treat dry mouth, swelling of the abdomen due to constipation, constipation and restlessness. .
한국공개특허 제1999-0084271호에서는 결명자 또는 결명자엽과 다른 생약재를 혼합하고 단순 분쇄 및 배전하여 제조한 티백차가 변비개선에 효과가 있음을 설명하고 있고, 한국공개특허 제2003-0062493호는 결명자를 먼저 추출, 농축 후 분무건조하여 제조한 결명자 추출물 분말과 카스카라사그라다 추출분말 등을 혼합하여제조한 혼합침출차가 기호성이 우수하고 변비증상 개선 효과가 있음을 설명하고 있고, 상기 특허들은 결명자를 단순 분쇄하여 배전하거나, 추출 및 농축하여 건조한 것이거나, 또는 이들과 다른 변비 개선 효과가 있는 생약재와 혼합하는 것에 불과하였다.Korean Patent Laid-Open Publication No. 1999-0084271 discloses that a tea bag prepared by mixing a livestock or a livestock lobe with other herbal medicines and simply pulverizing and distributing the livestock tea is effective in improving constipation, and Korean Patent Publication No. 2003-0062493 discloses that a lumberjack First, it is explained that a mixed leach tea prepared by mixing Cassiae japonica extract powder and Cassara sagrada extract powder prepared by extraction, concentration and spray drying has excellent palatability and an effect of improving constipation symptoms. They are merely pulverized and distributed, or extracted and concentrated and dried, or mixed with herbal medicines having different constipation-improving effects.
그러나 본 발명자들은 전통적으로 오랫동안 사용되어 그 안전성을 검증받은 생약인 결명자를 유산균으로 발효시켜 얻은 결명자 유산균 발효물이 결명자 추출물에 비하여 변의 개수, 변의 수분 함량 또는 변의 중량을 증가시켜 변비를 개선하거나 치료하는 효과가 현저히 증진됨을 알게 되어 본 발명을 완성하였다.
However, the present inventors have found that fermented product of Lactobacillus lactic acid bacteria obtained by fermenting a herbal medicine, which is a herbal medicine which has been traditionally used for a long time and proved its safety, with lactic acid bacterium is improved or treated with constipation by increasing the number of sides, water content of side, The effect is remarkably improved, and the present invention has been completed.
본 발명의 목적은 오랫동안 사용되어 안전성이 높고 생약으로서 부작용 발생가능성이 적은 결명자를 활용하여 변의 수분 함량 및 중량을 증가시키는 효과가 현저히 증진된 변비 개선 또는 예방용 건강기능식품을 제공하는 것이다.It is an object of the present invention to provide a health functional food for improving or preventing constipation, which has been used for a long time, has a high safety, and has a significantly improved effect of increasing the moisture content and weight of a side by using a cleanser which is less likely to cause side effects as a herbal medicine.
본 발명의 또다른 목적은 오랫동안 사용되어 안전성이 높고 생약으로서 부작용 발생가능성이 적은 결명자를 활용하여 변의 수분 함량 및 중량을 증가시키는 효과가 현저히 증진된 변비 치료 또는 예방용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for the treatment or prevention of constipation, which has been used for a long time and has a high safety and an effect of increasing the moisture content and weight of the stomach by using a cleanser which is less likely to cause side effects as a herbal medicine.
본 발명의 또다른 목적은 오랫동안 사용되어 안전성이 높고 생약으로서 부작용 발생가능성이 적은 결명자를 활용하여 변의 개수, 변의 수분 함량 및 변의 중량 중에서 어느 하나 이상을 증가시키는 효과가 현저히 증진된 결명자 유산균 발효물의 제조방법을 제공하는 것이다.
Another object of the present invention is to provide a method for producing a luciferous fermentation product which is highly effective in increasing the number of feces, the moisture content of the feces and the weight of the feces, Method.
본 발명은 결명자 유산균 발효물을 유효성분으로 하는 변비 개선 또는 예방용 건강기능식품을 제공한다.The present invention provides a health functional food for improving or preventing constipation, which comprises a fermented product of a lactic acid fermentor of an active ingredient as an active ingredient.
상기 결명자 유산균 발효물은 결명자 추출물에 유산균을 접종하여 발효시켜 얻은 것일 수 있다.The fermented product of the Lactobacillus canceller may be obtained by fermenting lactic acid bacteria inoculated with the luciferase extract.
상기 결명자 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물일 수 있다.The Cassiae Extract may be an extract of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 유산균은 락토바실러스속, 비피도박테리움속, 류코노스톡속, 페디오코커스속, 엔테로코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균일 수 있다.The lactic acid bacteria may be any one or more lactic acid bacteria selected from the group consisting of Lactobacillus sp., Bifidobacterium sp., Leuconostoc sp., Pediococcus sp., Enterococcus sp. Lactic acid bacteria.
상기 건강기능식품은 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 또는 바(bar) 형태의 제제일 수 있다.The health functional food may be in the form of a capsule, tablet, powder, granule, liquid, ring, flake, paste, syrup, gel, jelly or bar.
또한 본 발명은 결명자 유산균 발효물을 유효성분으로 하는 변비 치료 또는 예방용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the treatment or prevention of constipation, comprising a fermented product of a lactic acid fermentor of an active ingredient as an active ingredient.
상기 결명자 유산균 발효물은 결명자 추출물에 유산균을 접종하여 발효시켜 얻은 것일 수 있다.The fermented product of the Lactobacillus canceller may be obtained by fermenting lactic acid bacteria inoculated with the luciferase extract.
상기 결명자 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물일 수 있다.The Cassiae Extract may be an extract of water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 유산균은 락토바실러스속, 비피도박테리움속, 류코노스톡속, 페디오코커스속, 엔테로코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균일 수 있다.The lactic acid bacteria may be any one or more lactic acid bacteria selected from the group consisting of Lactobacillus sp., Bifidobacterium sp., Leuconostoc sp., Pediococcus sp., Enterococcus sp. Lactic acid bacteria.
또한 본 발명은 결명자 추출물을 제조하는 단계; 및 상기 결명자 추출물에 유산균을 접종하여 발효시키는 단계;를 포함하는 변의 개수, 변의 수분 함량 및 변의 중량 중에서 어느 하나 이상을 증가시키는 결명자 유산균 발효물의 제조방법을 제공한다.
The present invention also relates to a method for producing a Cassia tumefaciens extract; And a step of inoculating and lyophilizing the Lactobacillus japonica extract with a lactic acid bacterium, wherein the method further comprises increasing the number of sides, the moisture content of the sides, and the weight of the sides.
본 발명의 결명자 유산균 발효물은 오랫동안 사용되어 안전성이 높고 생약으로서 부작용 발생가능성이 적으면서도, 부작용 문제로 건강기능식품에 사용이 금지된 자극성 변비 치료제인 센노사이드, 또는 비사코딜 및 도큐세이트나트륨을 유효성분으로 하는 상용화된 둘코락스에스와 동등한 변의 개수, 변의 수분 함량 및 변의 중량 중에서 어느 하나 이상을 증가시키는 효과를 나타내므로, 변비 치료 또는 예방용 약학 조성물 또는 변비 개선 또는 예방용 건강기능식품으로 활용될 수 있다.
The fermented product of the lactic acid bacteria of the present invention has been used for a long time and has high safety and is less likely to cause adverse side effects as a herbal medicine. However, sincoside, a drug for the treatment of irritable constipation, or bisacodyl and docusate sodium, , The water content of the side and the weight of the stomach, it can be used as a pharmaceutical composition for the treatment or prevention of constipation or as a health functional food for improving or preventing constipation. .
도 1은 실험예 1에서 용매를 달리한 결명자 추출물을 각각 다른 유산균으로 발효시켰을 때 발효시간 36 시간 및 72 시간에 측정한 pH의 변화를 통해 유산균 발효의 진행을 확인한 그래프로서, 도 1a는 제조예 1의 추출물, 도 1b는 제조예 2의 추출물, 도 1c는 제조예 3의 희석액을 각각 발효시킨 것이다.
도 2는 실험예 2의 다.에서 각 실험군의 변의 개수를 나타낸 그래프이다.
도 3은 실험예 2의 다.에서 각 실험군의 변의 중량을 나타낸 그래프이다.
도 4는 실험예 2의 라.에서 각 실험군의 실험동물을 희생시킨 후, 대장을 적출하여 수세한 후의 사진이고, 각각의 대장 사진 아래 표시한 점은 Carmine이 이동한 거리를 표시한 것이다.
도 5는 도 4의 Carmine 이동 거리를 나타낸 그래프이다.
도 6a는 실험예 3에서 제조예 2의 결명자 에탄올수용액 추출물의 HPLC-IT/TOP MS 패턴을 나타낸 것이고, 도 6b는 실험예 3에서 제조예 4의 결명자 유산균 발효물의 HPLC-IT/TOP MS 패턴을 나타낸 것이다.FIG. 1 is a graph showing the progress of fermentation of lactic acid bacteria through a change in pH measured at 36 and 72 hours after fermentation with a different lactic acid bacterium according to Experimental Example 1. FIG. 1, the extract of Preparation Example 2, and the dilution of Production Example 3, respectively.
2 is a graph showing the number of sides of each test group in Experimental Example 2. In FIG.
3 is a graph showing the weights of the sides of each experimental group in Experimental Example 2. FIG.
FIG. 4 is a photograph of the experimental animal of Experimental Example 2 after sacrificing the experimental animals of each experimental group and then collecting and washing the large intestine.
FIG. 5 is a graph showing a moving distance of Carmine in FIG.
FIG. 6A shows the HPLC-IT / TOP MS pattern of the aqueous solution of the aqueous solution of Cefditor of Preparation Example 2 in Experimental Example 3, and FIG. 6B shows the HPLC-IT / TOP MS pattern of the fermented product of the Cactus Lactobacillus of Preparation 4 in Experimental Example 3 .
본 발명은 결명자 유산균 발효물을 유효성분으로 하는 변비 개선 또는 예방용 건강기능식품에 관한 것이고, 또한 본 발명은 결명자 유산균 발효물을 유효성분으로 하는 변비 치료 또는 예방용 약학 조성물에 관한 것이며, 또한 본 발명은 결명자 추출물을 제조하는 단계; 및 상기 결명자 추출물에 유산균을 접종하여 발효시키는 단계;를 포함하는 변의 개수, 변의 수분 함량 및 변의 중량 중에서 어느 하나 이상을 증가시키는 결명자 유산균 발효물의 제조방법에 관한 것이다.The present invention relates to a health functional food for improving or preventing constipation, comprising a fermented product of a lactic acid fermented by a defective lactic acid bacteria as an active ingredient. The present invention also relates to a pharmaceutical composition for treating or preventing constipation, The invention relates to a method for the production of a cetacean extract; And a step of inoculating and lyophilizing the Lactobacillus japonica extract with the lactic acid bacterium, wherein at least one of the number of sides, the moisture content of the sides, To a process for producing fermented lactic acid bacteria.
상기 결명자는 초결명자(Cassia obtusifolia L.) 또는 결명자(Cassia tora L.)이고, 바람직하게는 한국에서 재배되는 결명자(Cassia tora L.)이다.The loser may be a Cassia obtusifolia L.) or Cassia tora L.), preferably gyeolmyeongja grown in Korea (Cassia tora L.).
상기 결명자 유산균 발효물은 결명자 추출물에 유산균을 접종하여 발효시켜 얻은 것일 수 있다.The fermented product of the Lactobacillus canceller may be obtained by fermenting lactic acid bacteria inoculated with the luciferase extract.
상기 추출물은 추출 원재료에 추출 용매를 처리하여 얻은 조추출물뿐만 아니라 조추출물의 가공물도 포함한다. 예를 들어, 결명자 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다. 상기 추출물은 상기 조추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. The extracts include crude extracts as well as crude extracts obtained by treating extraction raw materials with extraction solvents. For example, the Cassiae Extract can be prepared in powder form by an additional process such as vacuum distillation and lyophilization or spray drying. The extract also includes fractions obtained by further fractionating the crude extract.
상기 결명자 추출물은 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합용매의 추출물로서, 추출방법은 특별히 한정할 필요가 없다. The Cassiae Extract is an extract of water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, and the extraction method is not particularly limited.
용매로 물을 사용하는 경우 열수추출이 바람직하다. 예를 들어, 80 내지 105 ℃, 바람직하게는 90 내지 100 ℃의 물에서 0.5 내지 24 시간, 바람직하게는 1 내지 6 시간 추출할 수 있다. 용매로 열수를 사용하지 않더라도, 즉 결명자 분말을 냉수 또는 실온의 물에 희석하여 혼합한 희석액에서 결명자의 성분이 추출될 수 있다. 냉수 또는 실온의 물을 이용하여 결명자 성분을 추추ㅎ하는 경우 발효와 별도로 추출할 수도 있고, 유산균 접종하여 발효되는 과정에서 결명자로부터 결명자의 성분이 용출되도록 할 수도 있다. When water is used as the solvent, hot water extraction is preferred. For example, at a temperature of 80 to 105 DEG C, preferably 90 to 100 DEG C for 0.5 to 24 hours, preferably 1 to 6 hours. Even if no hot water is used as a solvent, the components of the cleanser can be extracted from the diluted solution obtained by diluting the cuticle powder with cold water or water at room temperature. When cold water or room temperature water is used to extract the components of the lucifer, it may be extracted separately from the fermentation. In the fermentation by lactic acid bacteria inoculation, the lucifer may be eluted from the lucifer.
상기 탄소수 1 내지 4의 알코올 수용액에 의한 추출물이 사용될 수 있다. 예를들어, 에탄올, 메탄올, 이소프로판올 등의 알코올 수용액, 바람직하게는 20 내지 80 중량%의 알코올 수용액, 더욱 바람직하게는 50 내지 70 중량%의 알코올 수용액으로 추출한다. 알코올 추출물을 사용하는 경우 유산균을 접종하기 전 먼저 알코올 추출물의 알코올을 기화시켜 알코올 함량을 낮춘 농축액 또는 알코올 추출물을 농축 및 건조시킨 후 물에 용해한 후 사용한다. An extract of an aqueous solution of an alcohol having 1 to 4 carbon atoms can be used. For example, extraction is carried out with an alcohol aqueous solution such as ethanol, methanol or isopropanol, preferably 20 to 80% by weight aqueous alcohol solution, more preferably 50 to 70% by weight aqueous alcohol solution. When alcohol extracts are used, concentrate or dry the alcohol concentrate or alcohol extract, which has lowered the alcohol content, by evaporating alcohol from the alcohol extract before inoculation of the lactic acid bacteria, and dissolve in water before use.
또한, 본 발명에서 결명자 추출물은 넓은 의미로는 결명자 분말을 물에 희석한 희석액을 포함한다. 본 발명의 실험예에서 결명자 열수 추출물 또는 결명자 에탄올수용액 추출물을 유산균 발효시킨 유산균 발효물에 비하여, 결명자 물 희석액을 유산균으로 발효시킨 유산균 발효물의 변비 개선, 치료 또는 예방 효과가 다소 낮지만, 유산균 발효시키지 않은 결명자 추출물에 비해서는 그 효과가 유의적으로 증대되었음을 확인할 수 있었다.Also, in the present invention, the Cassiae Extract includes, in a broad sense, a diluted solution in which the Cassiae powder is diluted with water. In the experimental example of the present invention, the fermented product of fermented lactic acid bacteria obtained by fermenting the water-diluted lysate of the luciferase with the fermented product of lactic acid bacteria is somewhat lower than the fermented product of fermented lactic acid bacteria, And the effect was significantly increased compared to the non - Cassiae extract.
상기 결명자 추출물에 유산균을 접종하기 전에 유산균 생육을 증진시키기 위하여 단백질원, 탄수화물원, 비타민 또는 무기질 등의 유산균 영양원을 추가로 혼합할 수 있다. 상기 유산균 영양원은 시중에 판매되는 배지를 이용하거나 또는 필요한 영양원만을 개별적으로 첨가할 수 있다.A lactic acid bacteria nutrient source such as a protein source, a carbohydrate source, a vitamin or an inorganic source may be further mixed to enhance the growth of lactic acid bacteria before the lactic acid bacteria are inoculated into the Cassiae Extract. The lactic acid bacteria nutrient source may be supplemented with commercially available media or only necessary nutrients.
또한 상기 결명자 추출물, 또는 결명자 추출물과 유산균 영양원의 혼합물은 유산균을 접종하기 전에 가열살균할 수 있다.Also, the above-mentioned Cassiae Extract, or a mixture of the Cassiae Extract and the Lactobacillus nutrient source, may be sterilized by heating before the lactic acid bacteria are inoculated.
상기 결명자 추출물의 고형분 함량은 특별히 한정할 필요는 없으나 추출 후 다른 농축 과정이 없을 경우 1 내지 15 중량%이고, 이를 바로 사용할 수도 있고, 농축하여 사용할 수도 있으며, 농축 또는 건조한 후 희석하여 사용할 수도 있다.The solid content of the Cassiae Radix Extract is not particularly limited, but may be 1 to 15% by weight when there is no other concentration process after extraction, and may be directly used, concentrated or used, concentrated or dried and then diluted.
상기 유산균은 락토바실러스속, 비피도박테리움속, 류코노스톡속, 페디오코커스속, 엔테로코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균일 수 있다. 바람직하게 상기 유산균은 락토바실러스 파라카제이, 락토바실러스 케피리, 락토바실러스 애시도필러스, 비피도박테리움 롱검, 비피도박테리움 브레비스, 류코노스톡 메센테로이데스, 페디오코터스 펜토사세우스, 엔테로코커스 페칼리스이다.The lactic acid bacteria may be any one or more lactic acid bacteria selected from the group consisting of Lactobacillus sp., Bifidobacterium sp., Leuconostoc sp., Pediococcus sp., Enterococcus sp. Lactic acid bacteria. Preferably, the lactic acid bacteria are selected from the group consisting of Lactobacillus paracasei, Lactobacillus capryi, Lactobacillus acidophilus, Bifidobacterium longbum, Bifidobacterium brevis, Leuconostomes teneroides, Pediococcus pentosaceus, It's an enterococcus pecalis.
상기 발효 조건은 일반적인 유산균 발효와 동일하므로 특별히 한정할 필요는 없으나, 25 내지 40 ℃에서 24 내지 96 시간 수행될 수 있다.The fermentation conditions are the same as those of general lactic acid bacteria fermentation, so that the fermentation conditions are not particularly limited, but they may be carried out at 25 to 40 DEG C for 24 to 96 hours.
상기 결명자 유산균 발효물은 유산균 균체를 포함하는 발효물일 수 있고, 유산균 균체가 제거된 발효물일 수도 있다. 유산균 균체가 제거된 발효물은 발효물을 멸균하여 사균체를 포함하게 할 수도 있고, 여과 또는 원심분리를 통해 균체를 제거한 여액 또는 원심분리 상등액일 수 있다. 본 발명의 변비의 개선, 치료 또는 예방 효과는 결명자 추출물에 포함된 성분을 유산균이 증식하면서 생체 내에서 이용하기 용이한 성분으로 생물전환시키거나, 변비의 개선, 치료 또는 예방 효과를 갖는 신규의 활성 성분이 생성되기 때문으로 예상되며, 단순한 유산균 자체가 부가되어 얻을 수 있는 효과보다 현저히 상승된 것이다. 상기 결명자 유산균 발효물은 액상의 발효물을 그 자체로 사용할 수도 있고, 이를 건조하여 분말화할 수도 있다.The fermented product of the Lactobacillus canceller may be a fermented product containing lactic acid bacterium cells or a fermented product from which lactic acid bacterium cells have been removed. The fermented product from which the lactic acid bacterium cells have been removed may be sterilized to contain the dead cells, or may be filtrated or centrifuged by removing the cells through filtration or centrifugation. The improvement, treatment, or prevention effect of constipation according to the present invention can be achieved by a composition comprising a component of the Cassiae Extract, which is biologically converted into a component that is easy to use in vivo while the lactic acid bacteria multiply, Components are expected to be produced, and the effect obtained by adding the simple lactic acid bacteria itself is remarkably increased. The fermented product of the Lactobacillus canceller may be used as the fermented product itself or may be dried and pulverized.
본 명세서에서 용어 ‘유효성분으로 포함하는’이란 본 발명의 결명자 유산균 발효물의 변비 개선, 치료 또는 예방 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the improvement, treatment, or prevention efficacy or activity of the fermentation product of the deficiency lactic acid bacteria of the present invention.
상기 건강기능식품이란, 상기 결명자 유산균 발효물을 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 또는 바(bar) 형태로 제제화 한 것일 수 있고, 또는 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하여 일반 식품 형태로 제조한 것으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. The health functional food may be a product obtained by formulating the fermented product of the Lactobacillus lucidum in the form of a capsule, tablet, powder, granule, liquid, ring, flake, paste, syrup, gel, jelly or bar, It is produced in the form of general food added to food materials such as tea, spices, gum and confectionery. It means to bring about a certain effect in health when ingested. However, unlike general medicine, There is an advantage that there is no side effect that can occur when taking.
상기 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 결명자 유산균 발효물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 캡슐, 정제, 분말, 과립, 액상, 환, 편상, 페이스트상, 시럽, 겔, 젤리 또는 바(bar) 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. The health functional foods are very useful because they can be ingested routinely. The added amount of the fermented product of the lactic acid bacteria in the health functional food is not uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not deteriorate the original taste of the food, 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In the case of health functional foods in the form of capsules, tablets, powders, granules, liquids, pellets, slices, pastes, syrups, gels, jellies or bars, the amount is usually 0.1 to 100% by weight, preferably 0.5 to 80% %.
상기 건강기능식품은 유효성분으로서 결명자 유산균 발효물 뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 건강기능식품이 드링크제와 음료류로 제조되는 경우에는 본 발명의 홍경천 발효물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The health functional food may contain, as an active ingredient, not only the fermented product of the Lactobacillus lactic acid bacteria but also a component that is ordinarily added at the time of food production, for example, a protein, a carbohydrate, a fat, a nutrient, a seasoning agent and a flavoring agent . Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the health functional food of the present invention is prepared from a drink and a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, various plant extracts and the like may be further added have.
또한 결명자 유산균 발효물을 유효성분으로 하는 변비의 치료 또는 예방용 약학 조성물에서, 결명자 유산균 발효물은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 이상, 보다 더욱 더 바람직하게는 250 mg/kg 이상, 가장 바람직하게는 0.1 g/kg 이상 포함된다. 결명자 유산균 발효물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 결명자 유산균 발효물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.In a pharmaceutical composition for the treatment or prevention of constipation, wherein the fermented product is a fermented product of a Lactobacillus, for example, 0.001 mg / kg or more, preferably 0.1 mg / kg or more, more preferably 10 mg / kg or more, more preferably 100 mg / kg or more, even more preferably 250 mg / kg or more, and most preferably 0.1 g / kg or more. Since the fermented product of lactic acid bacteria as a natural product has no adverse effect on the human body even when administered in an excessive amount, the quantitative upper limit of the fermented product of the lactic acid bacteria of the present invention can be selected by a person skilled in the art within a suitable range.
상기 약학 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A flavoring agent and the like can be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제제화할 수 있다.The pharmaceutical composition may be formulated to contain at least one pharmaceutically acceptable carrier in addition to the above-described effective ingredients for administration.
상기 약학 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The pharmaceutical form of the pharmaceutical composition may be a granule, a powder, a tablet, a coated tablet, a capsule, a suppository, a liquid, a syrup, a juice, a suspension, an emulsion, a drip agent or an injectable liquid agent. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약학 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, And other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
상기 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition may be administered orally or parenterally. In the case of parenteral administration, the pharmaceutical composition may be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration or the like, preferably oral administration.
상기 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 바람직한 구현예에 따르면, 상기 약학 조성물의 1일 투여량은 0.001-10g/㎏이다.The appropriate dosage of the pharmaceutical composition will vary depending on factors such as the formulation method, the manner of administration, the age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, The physician can easily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment, the daily dosage of the pharmaceutical composition is 0.001-10 g / kg.
상기 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical composition may be prepared in a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Into a capacity container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
이하, 본 발명을 하기 실시예를 참조하여 더욱 구체적으로 설명하기로 한다. 다만, 하기 실시예는 본 발명의 이해를 돕기 위한 것일 뿐, 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described more specifically with reference to the following examples. However, the following examples are provided only to aid understanding of the present invention, and the scope of the present invention is not limited to the following examples.
제조예Manufacturing example 1: 결명자 1: 열수Heat number 추출물의 제조 Preparation of extract
결명자는 전남생약농업협동조합(화순군)에서 구입한 국내산 결명자(Cassia tora L.)를 정선, 수세 후 분쇄기로 균일하게 분쇄하여 평균입자크기 300 ㎛의 결명자 분말을 제조하여 냉장보관하면서 이용하였다. Cassia tora L., purchased from Jeonnam Agricultural Products Agricultural Cooperative Association (Hwasun Gun), was crushed uniformly with a crusher after washing with water Cristobator powder with an average particle size of 300 ㎛ was prepared and used in refrigeration.
상기 분쇄된 결명자 중량의 10 배의 증류수를 환류추출기에 넣고 100 ℃, 3시간 동안 2회 추출한 후, 방냉하고 여과한 다음 감압농축기로 농축하여 동결건조하여 결명자 열수 추출물 분말을 얻었다. 수율은 2.2 %이었다.
The distilled water, which was 10 times the weight of the crushed killer, was put into a reflux extractor and extracted twice at 100 ° C for 3 hours, followed by cooling and filtration, followed by concentration with a vacuum concentrator and lyophilization to obtain a scalded hot-water extract powder. The yield was 2.2%.
제조예Manufacturing example 2: 결명자 에탄올수용액 추출물의 제조 2: Preparation of Aqueous Solution Extract of Cereals
상기 제조예 1의 분쇄된 결명자 중량의 4 배의 50 중량% 주정에탄올 수용액을 첨가하여 3일 동안 실온에서 추출한 후, 여과한 다음 감압농축기로 농축하여 동결건조하여 결명자 에탄올수용액 추출물 분말을 얻었다. 수율은 9.8 %이었다.
Fourfold 50% by weight aqueous ethanol solution of the crude crushed lysate of Preparation Example 1 was added thereto, and the mixture was extracted at room temperature for 3 days. The mixture was filtered, concentrated using a vacuum concentrator, and lyophilized to obtain an aqueous solution of the aqueous ethanol extract of the lucifer. The yield was 9.8%.
제조예Manufacturing example 3: 결명자 물 Three: 희석액의Dilute 제조 Produce
상기 제조예 1의 분쇄된 결명자를 7 중량%가 되도록 물을 혼합하여 결명자 물 희석액을 제조하였다.
The water-diluted lysate was prepared by mixing water so that the crushed killer of Preparation Example 1 was 7% by weight.
제조예Manufacturing example 4: 4: 결명자 유산균 Lactic acid bacteria 발효물Fermentation product 의of 제조 Produce
상기 제조예 1 또는 2의 결명자 추출물 분말을 증류수에 5 중량%로 희석한 결명자 추출물, 또는 제조예 3의 결명자 물 희석액을 121 ℃, 1.5기압, 15분간 멸균한 다음, 표 1의 유산균을 각각 MRS broth와 GAM broth를 이용하여 24시간, 37 ℃에서 정치 배양하여 활성화시킨 후, 유산균을 배양액 5 중량%(1×107 CFU/㎖)를 상기 결명자 추출물에 각각 접종하여 37 ℃에서 72시간 동안, 150 rpm으로 교반하면서 배양하여 얻은 배양액을 얻었다. The lactic acid bacteria of the Cassia tora extract, or Cassia tora water diluted solution of Production Example 3 diluted Cassia tora extract powder of Preparation Example 1 or 2 to 5% by weight in distilled water, sterilized 121 ℃, 1.5 atm, for 15 minutes, Table 1, each MRS broth and GAM broth for 24 hours at 37 ° C to activate the culture. Lactic acid bacteria were inoculated into the Cassiae Extract at a concentration of 5% by weight (1 × 10 7 CFU / ml) And cultured at 150 rpm with stirring to obtain a culture solution.
상기 배양액을 4 ℃에서 6,000 rpm에서 15 분 원심분리하여 균체가 제거된 상등액을 농축 및 동결건조하여 결명자 유산균 발효물 분말을 제조하였다.The culture broth was centrifuged at 6,000 rpm for 15 minutes at 4 ° C, and the supernatant, from which the cells were removed, was concentrated and lyophilized to prepare a fermented product of the cultivar Lactobacillus.
분리From Tibetan mushrooms
detach
실험예Experimental Example 1: 결명자 유산균 1: Lactic acid bacteria 발효물의Fermented 발효특성 확인 Identification of fermentation characteristics
제조예 4의 결명자 유산균 발효물의 발효특성을 확인하기 위하여, 접종 후 36 및 72시간째에 발효물의 pH 및 생균수의 변화를 확인하였다. In order to confirm the fermentation characteristics of the fermented product of the Lactobacillus koreans in Preparation Example 4, the pH and viable cell count of the fermented product were checked at 36 and 72 hours after inoculation.
생균수는 생균수는 시료 1ml를 멸균 생리식염수 9ml에 희석하고 잘 섞은 후 단계별로 희석한 다음 0.1ml을 취하여 Lactobacillus속, Pediococcus속은 MRS agar에 도말하고, Bifidobacterium속은 5%의 horse blood를 함유한 BL agar에 도말하여 anaerobic jar (BBL Gas Pak Anaerobic System)를 이용하여 최대한 혐기적인 상태로 보관하여 37 ℃에서 24-48시간 배양한 후 생성된 집락수를 계측하고, 그 평균 집락 수에 희석배수를 곱하여 배양액 당 colony를 산출하였다.
Lactobacillus spp., Pediococcus spp. Were plated on MRS agar, and Bifidobacterium spp. Was blended with 5% horse blood containing 5% horse blood. The viable cell count was determined by diluting 1 ml of the sample with 9 ml of sterile physiological saline, agar and anaerobic jar (BBL Gas Pak Anaerobic System). After incubation at 37 ° C for 24-48 hours, the number of colonies formed was counted, and the average number of colonies was multiplied by the dilution factor Colony per culture was calculated.
가. end. pHpH 변화 change
유산균의 종류 및 배양시간에 따른 pH 변화를 도 1a, 도 1b 및 도 1c에 나타내었다. 도 1a는 제조예 1의 추출물, 도 1b는 제조예 2의 추출물, 도 1c는 제조예 3의 희석액을 각각 발효시킨 것이다.The types of lactic acid bacteria and pH changes with time of culture are shown in Figs. 1A, 1B and 1C. Fig. 1 (a) is the extract of Preparation Example 1, Fig. 1 (b) is the extract of Preparation Example 2, and Fig. 1 (c) is the fermentation of the dilution of Production Example 3.
초기 pH는 6.4 이었으며, 36 시간째에 5.2 내지 5.8로 감소하였고, 72 시간째에 4.9 내지 5.5로 감소하였다.The initial pH was 6.4, decreased from 5.2 to 5.8 at 36 hours, and decreased from 4.9 to 5.5 at 72 hours.
유산균별로 pH의 변화를 비교하면 Lactobacillus kefiri MJ90(L1) 및 Lactobacillus paracasei(L2)가 Lactobacillus acidophillus 128(L3), Lactobacillus plantarum 144(L4), Bifidiobacterium longum(B1), Pediococcus pentosaceus(P1) 보다 상대적으로 큰 폭으로 감소하였다.Comparing changes in pH by lactic acid bacteria Lactobacillus kefiri MJ90 (L1) and Lactobacillus paracasei (L2) Lactobacillus acidophilus 128 (L3) , Lactobacillus plantarum 144 (L4), Bifidiobacterium longum (B1) , Pediococcus pentosaceus (P1).
유산균이 동일할 경우 기질로 제조예 1의 결명자 열수 추출물, 제조예 2의 결명자 에탄올 추출물, 제조예 3의 결명자 물 희석액을 사용하는 배양액의 pH에는 거의 차이가 없었고, 제조예 3 경우 나머지에 비해 36 시간째 및 72 시간째의 pH가 다소 높았다.When the lactic acid bacteria were the same, there was almost no difference in the pH of the cultured medium using the scalded hot water extract of Preparation Example 1, the Casser's ethanol extract of Preparation Example 2, The pH at the time and 72 hours was somewhat higher.
나. I. 생균수Viable cell count 변화 change
유산균 6종 중에서 pH 변화가 상대적으로 크게 나타났던 유산균 2종(L1 및 L2)을 다시 전 배양하고 균주의 성장능을 알아보기 위하여 고형분 함량 6 중량%의 결명자 추출물에 유산균을 각각 1 중량%씩 접종하고 37 ℃에서 24 시간 발효한 후 생균수를 측정하여 그 결과를 표 2에 나타내었다. Two kinds of lactic acid bacteria (L1 and L2) which had relatively high pH change among 6 kinds of lactic acid bacteria were re-preincubated and inoculated with 1% by weight of lactic acid bacteria in a 6% And the number of viable cells was measured after fermentation at 37 ° C for 24 hours. The results are shown in Table 2.
상기 표 2에 나타낸 바와 같이 기질로 제조예 1의 결명자 열수 추출물을 사용한 것과 제조예 2의 에탄올수용액 추출물을 사용한 것에서 거의 차이가 없었으나, 제조예 3의 결명자 물 희석액을 사용한 것에서는 발효 후 생균수가 제조예 1 및 2의 생균수의 절반에 조금 못 미치는 수준이었다.As shown in the above Table 2, there was almost no difference between the use of the hydrothermal extract of Cercillator in Preparation Example 1 and the ethanol aqueous solution of Preparation Example 2 as the substrate, but in the case of using the dilution liquid of Cercillation Water of Preparation Example 3, Which was slightly less than half of the viable cell counts of Production Examples 1 and 2.
Lactobacillus kefiri MJ90(L1) 균주를 사용하여 제조한 배양액의 생균수가 Lactobacillus paracasei(L2) 균주를 사용하여 제조한 배양액의 생균수 보다 3 배 정도 많음을 확인할 수 있었다.
Lactobacillus It was confirmed that the number of viable cells of the culture prepared by using the kefiri MJ90 (L1) strain was three times higher than the number of viable cells of the culture prepared using the Lactobacillus paracasei (L2) strain.
실험예Experimental Example 2: 동물실험을 통한 효과 확인 2: Confirmation of effect through animal experiment
가. 실험동물 및 end. Experimental animals and 실험군Experimental group
실험동물은 SD(Sprague Dawley) 래트 4주령 수컷을 다물사이언스(대전)에서 구입하여 사용하였으며, 온도 20±2 ℃, 습도 55±5 %, 12 시간 명암조건에서 사육하였다. 실험동물은 구입 후 1주일 동안 순화한 다음, 각 군당 5마리씩을 배치하여 표 3과 같이 실험군을 설정하였다. Male, 4-week-old SD (Sprague Dawley) rats were purchased from Multiscience (Daejeon) and used for breeding at a temperature of 20 ± 2 ° C and a humidity of 55 ± 5% for 12 hours. Experimental animals were purified for 1 week after purchase, and 5 mice per group were placed in the experimental group as shown in Table 3.
로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군Sennoside 50 mg / kg After one week oral administration,
Lipheramide 4 mg / kg subcutaneously for 5 days Positive control
로페라미드 5일동안 4 mg/kg 피하투여한 양성 대조군After oral administration of Dulcolax S 36.25 mg / kg per week,
Lipheramide 4 mg / kg subcutaneously for 5 days Positive control
로페라미드 5일동안 4 mg/kg 피하투여After oral administration of 200 mg / kg of the water-extract of Cercariae of Preparation Example 1 for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여After 200 mg / kg of a water extract of Cercariae of Preparation Example 2 for 1 week orally,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 1 Fermentation product of strain L1 (Preparation Example 4) After oral administration of 100 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 1 Fermentation product of strain L1 (Preparation Example 4) After oral administration of 200 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 2 Fermentation product of strain L1 (Preparation Example 4) After oral administration of 100 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 2 Fermentation product of strain L1 (Preparation Example 4) After oral administration of 200 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 3 After the oral administration of 100 mg / kg of the fermentation product of the strain L1 (Production Example 4) for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 3 After the oral administration of 100 mg / kg of the fermentation product of the strain L1 (Production Example 4) for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 2 Fermentation of strain L2 (Preparation Example 4) After oral administration of 100 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
로페라미드 5일동안 4 mg/kg 피하투여Production Example 2 Fermentation product of strain L2 (Preparation Example 4) After oral administration of 200 mg / kg for 1 week,
4 mg / kg subcutaneous administration of rofemide for 5 days
제조예2 추출물의 L1균주 발효물(제조예4) 200 mg/kg 1주일 경구투여Loperamide was subcutaneously administered at 4 mg / kg for 5 days,
Production Example 2 Fermentation product of strain L1 (Preparation Example 4) 200 mg / kg per 1 week oral administration
정상 대조군(NOR), 음성 대조군(LOP) 및 실시예 5를 제외한 각 실험군은 로페라미드 투여 전에 각각의 양성 대조군 약물이나 비교예 및 실시예의 시료를 5 일동안 경구 투여하였다.Each of the experimental groups except for the normal control (NOR), the negative control (LOP) and the Example 5 were orally administered the respective positive control drugs, the samples of the comparative examples and the examples for 5 days before the administration of the looperamide.
정상 대조군(NOR)을 제외한 음성 대조군(LOP), 양성 대조군(CON1, CON2) 및 실시예 5를 제외한 모든 실시예들은 로페라미드를 5일 동안 피하투여하여 변비를 유발하였고, 로페라미드 투여개시일로부터 6 일째 실험동물을 희생시켰다.All but the negative control (LOP), the positive control (CON1, CON2) except for the normal control (NOR), and the Example 5 resulted in constipation by subcutaneous administration of rofelamide for 5 days, Lt; RTI ID = 0.0 > 6 < / RTI >
실시예 5는 음성 대조군(LOP)과 동일하게 로페라미드를 5일 동안 피하투여하여 변비를 유발시킨 후, 실시예 2-2와 동일한 제조예2 추출물의 L1균주 발효물(제조예4) 200 mg/kg 5일 경구투여후, 마직막 발효물 투입 다음날 실험동물을 희생시켰다.
In Example 5, Fermented Lactobacillus Lactobacillus strain Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus Lactobacillus (LOP) mg / kg After 5 days of oral administration, the last day of the addition of the final fermentation animals were sacrificed.
나. 체중, 사료 섭취량 및 I. Weight, feed intake and 음수량Quantity of water
실시예 5를 제외한 모든 실험군은 로페라미드 투여개시일부터 실험동물 희생시킬 때까지, 실시예 5는 로페라미드 발효물 투여개시일부터 실험동물을 희생시킬 때까지의 실험동물의 체중변화량(g), 사료 섭취량(g) 및 음수량(mL)을 표 4에 나타내었다.All experimental groups except for Example 5 were divided into two groups: from the start of ropelamide administration to the sacrifice of experimental animals, Example 5 shows the change in body weight (g) of experimental animals from the start of administration of ferulamide fermented product to sacrifice of experimental animals, Feed intake (g) and water volume (mL) are shown in Table 4.
상기 실험기간 동안 사료섭취량 및 음수량에는 유의적인 차이가 없었고, 체중증가량에 있어서도 유의적인 차이를 보이지 않았다.
There was no significant difference in feed intake and insulin intake during the experiment and no significant difference in body weight gain.
다. 변의 개수 및 중량All. Number of sides and weight
실시예 5는 발효물 투여개시일로부터 4일째, 나머지는 로페라미드 투여개시일부터 4일째에 케이지 안의 변을 제거하고 베드를 갈아준 후 1일 동안 변을 수거하여 변의 개수 및 변의 중량을 측정하여 각각 도 2 및 도 3에 나타내었다. In Example 5, the sides of the cage were removed from the cage for 4 days from the start of fermentation, and the rest were removed from the cage for 4 days from the start of ropelamide administration. The sides were collected for 1 day after the bed was changed, 2 and 3.
변의 개수는 정상 대조군(NOR)이 47.2 ± 5.8 개인 것에 비해, 로페라미드 투여 음성 대조군(LOP)가 23.1 ± 3.6 개로 감소되어, 로페라미드에 의한 변비 유발이 확인되었고, 센노사이드(CON1)가 둘코락스에스(CON2)보다 변의 개수 증가 효과가 뛰어난 것을 확인할 수 있었다.The number of stools was reduced to 23.1 ± 3.6 compared with the control group (NOR) of 47.2 ± 5.8, and the ropeferramide negative control group (LOP) was reduced to 23.1 ± 3.6, It was confirmed that the effect of increasing the number of sides was better than that of Dulcolax S (CON2).
비교예 1 및 2의 결명자 물 추출물 및 결명자 에탄올수용액 추출물 투여군은 변의 개수 증가 효과가 거의 나타나지 않았고, 비교예 1 및 2와 동일하게 200 mg/kg 투여한 실시예 1-2, 2-2 및 4-2에서는 센노사이드(CON1)과 동등한 변의 개수 증가 효과를 나타내었다. 실시예 3-2에서는 센노사이드보다는 다소 낮지만 둘코락스에스와 동등한 변의 개수 증가 효과를 나타내었다.In Comparative Examples 1 and 2, the water extract of the Cassiae and the aqueous solution of the aqueous ethanol solution of the categorizer showed little effect of increasing the number of sides, and in Examples 1-2 and 2-2 and 4 -2 showed the effect of increasing the number of sides equivalent to sennoside (CON1). In Example 3-2, the number of sides equivalent to Dulcolax S was increased although it was somewhat lower than that of senoside.
실시예 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1 및 4-2는 용량 의존적으로 변의 개수 증가 효과가 증가하였고, L1 균주를 이용하여 발효시킨 실시예 2-1 및 2-2에서 변의 개수 증가 효과가 더 높았고, 동일하게 L1 균주로 발효시킨 경우에도 결명자 에탄올수용액 추출물을 발효시킨 실시예 2-1 및 2-2가 실시예 1-1 및 1-2 보다 변의 개수 증가 효과가 더 뛰어남을 확인하였다.The effect of increasing the number of sides was increased in the dose-dependent manner in Examples 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1 and 4-2, In Examples 2-1 and 2-2 in which fermentation was carried out, the effect of increasing the number of sides was higher, and also in the case of fermentation with the L1 strain in the same manner, in Examples 2-1 and 2-2 in which the aqueous solution of the aqueous ethanol solution of the cutter was fermented, 1 and 1-2, respectively.
변비를 유발한 후 제조예 2의 결명자 에탄올수용액 추출물의 L1 균주 발효물을 투여한 실시예 5에서는 변의 개수가 26.2 ± 3.1 개로 음성 대조군(LOP)에 비해 유의적으로 다시 증가하였다.
In Example 5, in which the L1 fermented product of the aqueous solution of the aqueous ethanol solution of the lysimeter of Preparation Example 2 was administered after inducing constipation, the number of the stools was 26.2 ± 3.1, which was significantly increased again compared with the negative control (LOP).
변의 중량 또한 정상 대조군(NOR)이 4.8 ± 0.89 개인 것에 비해, 로페라미드 투여 음성 대조군(LOP)가 2.6 ± 0.32 개로 감소되어, 로페라미드에 의한 변비 유발이 확인되었고, 센노사이드(CON1)와 둘코락스에스(CON2)의 변의 중량에는 유의적인 차이는 없었다.(LOP) was reduced to 2.6 ± 0.32 compared with 4.8 ± 0.89 in the normal control group (NOR), and the induction of constipation by ropelamide was confirmed. There was no significant difference in the weight of the sides of Dulcolax S (CON2).
비교예 1의 결명자 물 추출물 투여군은 변의 중량 증가 효과가 나타나지 않았으나, 비교예 2의 결명자 에탄올수용액 추출물 투여군은 변의 중량 증가 효과가 나타났다.Comparative Example 1 showed no effect of increasing the weight of the stomach in the water-extract-treated group of Comparative Example 1, but increased the weight of the stomach in the group treated with the aqueous solution of the aqueous ethanol solution of the Criterion of Comparative Example 2.
비교예 2와 동일하게 200 mg/kg 투여한 실시예 1-2 및 2-2에서는 비교예 2에 비해서 유의적으로 변의 중량이 증가하였고, 실시예 4-2에서는 비교예 2와는 유의적인 차이가 없었으나 비교예 1에 비해서는 유의적으로 변의 중량이 증가하였다. 실시예 3-2에서는 센노사이드 및 둘코락스에스와 동등한 변의 중량 효과를 나타내었다. As in Comparative Example 2, the weight of the stool was significantly increased in Examples 1-2 and 2-2 administered with 200 mg / kg, as compared with Comparative Example 2, and a significant difference was observed in Comparative Example 2 in Example 4-2 But the weight of the stool was significantly increased as compared with Comparative Example 1. In Example 3-2, the effect of weight on the sides equivalent to sennoside and Dulcolax S was shown.
실시예 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1 및 4-2는 용량 의존적으로 변의 중량 증가 효과가 증가하였고, 동일하게 L1 균주로 발효시킨 경우에도 결명자 에탄올수용액 추출물을 발효시킨 실시예 2-1 및 2-2가 실시예 1-1 및 1-2 보다 변의 중량 증가 효과가 더 뛰어났으며, L1 균주를 이용하여 발효시킨 실시예 2-1 및 2-2에서 L2 균주를 이용하여 발효시킨 실시예 4-1 및 4-2보다 변의 중량 증가 효과가 더 높게 나타났다.The effect of increasing the weight of the stomach was increased in a dose-dependent manner in Examples 1-1, 1-2, 2-1, 2-2, 3-1, 3-2, 4-1 and 4-2, In Examples 2-1 and 2-2 in which the aqueous solution of the aqueous ethanol solution of the cutter was fermented, the effect of increasing the weight of the stool was more excellent than those in Examples 1-1 and 1-2, 2-1 and 2-2, the weight increase effect of the stool was higher than those of Examples 4-1 and 4-2 fermented using the strain L2.
변비를 유발한 후 제조예 2의 결명자 에탄올수용액 추출물의 L1 균주 발효물을 투여한 실시예 5에서는 변의 중량이 3.18 ± 0.28 개로 음성 대조군(LOP)에 비해 유의적으로 다시 증가하였다.
In Example 5, in which the L1 fermented product of the aqueous solution of the aqueous ethanol solution of the Criterion of Preparation Example 2 was administered after inducing constipation, the weight of the stool was 3.18 ± 0.28, which was significantly increased again compared with the negative control (LOP).
라. la. CarmineCarmine 색소 장 이동 거리 Coloring matter movement distance
Carmine 색소 장 이동 거리는 carmine 색소를 생리식염수에 1.5% (w/v)농도로 하여 6일째에 3mL 경구투여 하였으며, 경구투여 20분 후에 실험동물을 희생시킨 후, 대장은 맹장 이후 부분부터 직장까지 부위의 양쪽을 결찰하여 적출하여, PBS로 장기를 수세한 후의 사진을 도 4에 나타내었고, 도 4에서 표시한 Carmine 색소가 이동한 거리를 측정하여 도 5에 나타내었다. The carmine pigment was transferred to saline at a concentration of 1.5% (w / v) in physiological saline. Oral administration of carmine dye was performed at 3 mL for 6 days. After 20 minutes of oral administration, FIG. 4 shows a photograph of the large intestine after ligating both the cecum to the rectum and washing the organs with PBS. The distance traveled by the Carmine pigment shown in FIG. 4 was measured and shown in FIG. .
Carmine 색소의 장 이동 거리는 정상 대조군(NOR)이 13.4 ± 0.94 cm인 것에 비해, 로페라미드 투여 음성 대조군(LOP)가 6.6 ± 0.75 cm로 감소되어, 로페라미드에 의한 변비 유발이 확인되었고, 센노사이드(CON1)와 둘코락스에스(CON2)는 장 이동 거리가 음성 대조군(LOP)에 비하여 현저히 증가하였다.The translocation distance of Carmine pigment was 13.4 ± 0.94 cm in the normal control group (NOR), and the negative control group (LOP) was decreased to 6.6 ± 0.75 cm in the ropeferramide administration, Side lengths (CON1) and Dulcolax es (CON2) increased significantly in the length of the bowel movement compared to the negative control (LOP).
비교예 1은 장 이동 거리에서 음성 대조군(LOP)와 유의차가 없었으나, 비교예 2는 음성 대조군(LOP)에 비해서 유의적으로 장 이동 거리가 증가하였다.In Comparative Example 1, there was no significant difference from the negative control group (LOP) in the long movement distance, but in the Comparative Example 2, the short movement distance was significantly increased as compared with the negative control group (LOP).
실시예 3-1 및 2-1에서는 비교예 2의 1/2 양으로 투여했음에도 비교예 2와 유사한 장 이동 거리를 나타내었고, 비교예 1 및 2와 동일 양을 투여한 실시예 3-2 및 2-2는 비교예 2에 비해서 현저히 장 이동 거리가 늘어남을 확인하였다.In Examples 3-1 and 2-1, although they were administered in ½ amount of Comparative Example 2, they showed a similar long-distance travel distance as Comparative Example 2, and in Examples 3-2 and 3-2 in which the same amount as in Comparative Examples 1 and 2 was administered, It was confirmed that the long travel distance of 2-2 was remarkably increased as compared with Comparative Example 2.
실시예 3-2 및 2-2는 양성대조군인 센노사이드 및 둘코락스에스와 동등하거나 그 이상의 장 이동 거리를 나타내었으며, 특히 L1 균주로 발효시킨 실시예 2-2는 정상 대조군(NOR)과 동등한 장 이동 거리를 나타내었다.
Examples 3-2 and 2-2 showed a field migration distance equal to or greater than that of the positive control selenoside and Dulcolax S, and in particular, Example 2-2 fermented with the L1 strain was equivalent to the normal control (NOR) And the distance of the longest movement.
실험예Experimental Example 3: 발효 전 후 3: Before and after fermentation HPLCHPLC -- ITIT // TOPTOP MSMS 패턴비교 Pattern comparison
제조예 2의 결명자 에탄올수용액 추출물 분말과 제조예 2의 결명자 에탄올 수용액 추출물 분말을 L1 균주로 발효시킨 제조예 3의 결명자 유산균 발효물 분말을 동일 농도로 HPLC-IT/TOP MS 기기(Shimadzu, 일본)를 이용하여 HPLC-IT/TOP MS를 실시하여 패턴을 비교하였다. Acquity UPLC C-18, 1.7m 2.1x100mm 컬럼으로, 유속 0.3 mL/min, 아세토니트릴 10% 수용액에서 70% 수용액으로 그래디언트로 측정하였다.IT / TOP MS device (Shimadzu, Japan) at the same concentration as that of Preparation Example 3, which was obtained by fermenting the aqueous solution of the aqueous solution of the aqueous solution of the decanter of Preparation Example 2 and the aqueous solution of the aqueous solution of the aqueous ethanol solution of the decanter of Preparation Example 2, Were used to perform HPLC-IT / TOP MS to compare patterns. Acquity UPLC C-18, 1.7 m 2.1 x 100 mm column, with a gradient of 70% aqueous solution in a 10% aqueous solution of acetonitrile at a flow rate of 0.3 mL / min.
제조예 2의 결명자 에탄올수용액 추출물의 패턴을 도 6a에 제조예 3의 결명자 유산균 발효물의 패턴은 도 6b에 나타내었다. 상기 패턴 비교를 통해 제조예 2의 결명자 에탄올 수용액 추출물 패턴에서 다수의 피크가 발효를 통해 함량이 낮아지거나 사라지고, 대신 새로운 피크가 생성됨을 확인하였다.The pattern of the aqueous solution of the aqueous solution of the lysate of Preparation Example 2 is shown in Fig. 6a, and the pattern of the fermented product of the Lactobacillus of Preparation Example 3 is shown in Fig. 6b. Through the above pattern comparison, it was confirmed that a large number of peaks were lowered or disappeared through fermentation in the aqueous solution of the aqueous ethanol solution of the liquor of Production Example 2, and a new peak was produced instead.
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140128784A KR101600884B1 (en) | 2014-09-26 | 2014-09-26 | Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient |
CN201410692371.0A CN105495150B (en) | 2014-09-26 | 2014-11-26 | Using cassia seed lactobacillus fermentation as the constipation improvement of effective ingredient, treatment or prevention composition and its manufacturing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140128784A KR101600884B1 (en) | 2014-09-26 | 2014-09-26 | Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101600884B1 true KR101600884B1 (en) | 2016-03-09 |
Family
ID=55537103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140128784A KR101600884B1 (en) | 2014-09-26 | 2014-09-26 | Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101600884B1 (en) |
CN (1) | CN105495150B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024160988A1 (en) * | 2023-02-01 | 2024-08-08 | Alfasigma S.P.A. | Fermentation product for use in the treatment of diseases associated with metabolic syndrome and hepatic steatosis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
CN108056461B (en) * | 2017-12-10 | 2021-04-30 | 牡丹江师范学院 | Black fungus chewable tablet with intestine moistening function and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR900001072B1 (en) * | 1987-09-15 | 1990-02-26 | 김중만 | Process for axtraction of cassia tora l. |
KR920002102B1 (en) * | 1989-12-28 | 1992-03-12 | 오뚜기식품 주식회사 | Process for making fermented beverage |
KR20030062493A (en) * | 2002-01-17 | 2003-07-28 | 주식회사 태평양 | Powder of Cassia Tora L. and tea containing the same for treating constipation |
KR100512322B1 (en) * | 2004-07-09 | 2005-09-02 | 김양문 | Double-fermented bio-zyme liquid having an improvement effect of constipation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4456160B2 (en) * | 2008-03-26 | 2010-04-28 | 株式会社フィス | Novel lactic acid strains and their use |
CN101331947B (en) * | 2008-06-12 | 2012-07-04 | 东莞锦泰食品有限公司 | Cookies formula with catharsis effect and preparation method thereof |
CN103908585B (en) * | 2013-01-05 | 2016-04-20 | 吴炳新 | For the probiotics fermention compositions of prevention and therapy constipation |
CN103387926A (en) * | 2013-07-18 | 2013-11-13 | 苏州市天灵中药饮片有限公司 | Fruit vinegar for clearing heat and moistening intestines and preparation method thereof |
CN103830711B (en) * | 2014-03-17 | 2016-10-12 | 郑州市中食农产品加工研究院 | A kind of method utilizing probiotics fermention to prepare artificial Ganoderma and health-care nutrient liquor |
-
2014
- 2014-09-26 KR KR1020140128784A patent/KR101600884B1/en active IP Right Grant
- 2014-11-26 CN CN201410692371.0A patent/CN105495150B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR900001072B1 (en) * | 1987-09-15 | 1990-02-26 | 김중만 | Process for axtraction of cassia tora l. |
KR920002102B1 (en) * | 1989-12-28 | 1992-03-12 | 오뚜기식품 주식회사 | Process for making fermented beverage |
KR20030062493A (en) * | 2002-01-17 | 2003-07-28 | 주식회사 태평양 | Powder of Cassia Tora L. and tea containing the same for treating constipation |
KR100512322B1 (en) * | 2004-07-09 | 2005-09-02 | 김양문 | Double-fermented bio-zyme liquid having an improvement effect of constipation |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024160988A1 (en) * | 2023-02-01 | 2024-08-08 | Alfasigma S.P.A. | Fermentation product for use in the treatment of diseases associated with metabolic syndrome and hepatic steatosis |
Also Published As
Publication number | Publication date |
---|---|
CN105495150B (en) | 2019-05-10 |
CN105495150A (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103027231B (en) | Compound probiotics fermented Chinese herbal medicine active health care liquid and preparation method thereof | |
JP6998613B2 (en) | A method for producing a composition for preventing, improving or treating the deterioration of intestinal function containing a bamboo shoot enzyme decomposition product or a bamboo shoot fermented product as an active ingredient. | |
CN107981324A (en) | Turmeric fermented food and preparation method thereof | |
KR20150110378A (en) | Composition comprising extract post-fermented tea | |
KR20200076157A (en) | Composition for improving, treating or preventing intestinal function or inflammarory bowel disease comprising fermented rice as an active ingredient | |
KR20150132616A (en) | Composition for enhancing immune response comprising extract of Apios americana Medikus or fermented extract of the same | |
KR101689192B1 (en) | Lactobacillus kefiri strain for enhancing activity of improving or preventing constipation by fermenting Cassia | |
KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
KR102263698B1 (en) | A mixture of Lactobacillus plantarum LRCC5195 and isomaltooligosaccharide having ameliorating or improving atopic dermatitis | |
KR101600884B1 (en) | Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient | |
KR101614929B1 (en) | A pharmaceutical composition for treating cognitive and memory impairment | |
KR102305931B1 (en) | A food composition for improving circulation of blood and increasing functions of immune comprising natural extracts | |
KR102167812B1 (en) | Fermented product of sorghum-adzuki bean mixture for intestinal health and improvement effect of bowel | |
KR101808306B1 (en) | Lactobacillus casei strain for enhancing activity of improving or preventing constipation by fermenting Cassia | |
KR102465484B1 (en) | Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing heat-killed enteroccocus faecalis as an active ingredient | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR101683030B1 (en) | A composition comprising the extract of fermented Curcuma longa L. and the compound extracted therefrom for preventing and treatment of cancer | |
KR102042151B1 (en) | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves | |
CN105707898A (en) | Toxin removing and bowel relaxing probiotic composition and preparation method and application thereof | |
KR20170011391A (en) | Composition for improving, treating or preventing constipation comprising fermented product of Cassia as an active ingredient | |
KR20040018569A (en) | Development of probiotic agent using salicornia herbacea | |
KR20200098224A (en) | Prebiotics comprising polysaccharide from residues of immature citrus extract or immature citrus peel and composition comprising the same as an active ingredient for promoting probiotics proliferation | |
KR102430399B1 (en) | A composition for improving, preventing and treating of gastrointestinal disease | |
KR102036860B1 (en) | A composition as a prebiotic for improving intestinal microflora containing corchorous olitorius | |
KR102552609B1 (en) | Composition for improving memory and learning ability and relieving stress |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20181231 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 5 |